6月26日，广州资本市场支持民营企业高质量发展系列之广州市"领头羊"产融对接活动第28期生物医药 专场路演活动在第14届中国（广州）国际金融交易·博览会上成功举办。 本次活动由广东股权交易中心、广州金融发展服务中心主办，广州科技金融路演中心、深交所创新创业 投融资服务平台（深交所科融通V-Next）、广东省创业投资协会协办，多家投资机构和金融机构代表等 120余人参加活动。 力之医疗科技（广州）有限公司联合创始人、总经理陈彦接受广州日报记者采访时表示，"政府非常支 持民营企业发展，给我们'送人、送钱、送场景'。"除了积极助力公司与高校、金融机构的对接，政府 机构还帮助企业开拓渠道资源，让产品快速推进到实用场景中。 当前，广州市正在加快建设"12218"现代化产业体系，其中"生物医药与健康"定位为6个新兴支柱产业之 一，"生物制造"位列5个战略先导产业，生物医药与大健康产业已成为广州市重点布局产业。下一步， 广东股权交易中心和广州金融发展服务中心将在广州市委金融办的指导下，充分发挥广州资本市场融资 对接服务平台作用，进一步细化产融对接服务举措，推动资本市场服务重点产业链企业更加精准、高 效，加快创新链、人才链、 ...

Group 1 - The company, 泰德医药 (Tide Pharmaceutical), plans to globally offer 16.8 million H-shares, with 1.68 million shares available in Hong Kong and 15.12 million shares for international offering [1] - The subscription period for the shares is set from June 20 to June 25, 2025, with the expected pricing date on June 26, 2025, and trading on the Hong Kong Stock Exchange anticipated to start on June 30, 2025 [1] - The proposed price range for the shares is between HKD 28.40 and HKD 30.60, with a trading unit of 100 shares [1] Group 2 - According to Frost & Sullivan, the company is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023 [2] - The company provides a full cycle of services from early discovery, preclinical research, clinical development to commercial production, primarily focusing on API rather than finished drugs [2] - The company has established stable customer relationships in over 50 countries, including major markets such as China, the USA, Japan, Europe, South Korea, and Australia [2] Group 3 - The company has signed cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of 2.6608 million shares at a hypothetical price of HKD 29.50, amounting to approximately USD 10 million (around HKD 78.49 million) [3] - The estimated net proceeds from the global offering are approximately HKD 411.2 million, assuming a share price of HKD 29.50 [3] - The intended use of the net proceeds includes approximately 76.4% for expanding service capacity and production facilities in the USA and China, 4.1% for expanding capacity in China, 9.5% for establishing sales and after-sales service networks in more regions, and 10.0% for working capital and other general corporate purposes [3]

Core Viewpoint - The health industry is becoming increasingly important for national and public welfare, with Lishan Health (Shandong) Group Co., Ltd. positioning itself as a key player in the biopharmaceutical sector, integrating social responsibility into its business development [1][14]. Group 1: Biopharmaceutical Development - The biopharmaceutical industry is a strategic emerging sector crucial for national welfare and global technological competition, with Lishan Health driving innovation and integrating into the "Healthy China 2030" strategy [2]. - Lishan Health has established a CDMO pilot base for immune cell and gene therapy, focusing on drug discovery and clinical research, supported by three major technological platforms [2][7]. - The company has achieved significant milestones in technology innovation, with 28 authorized intellectual properties and 4 projects recognized by Shandong Province, contributing to the rapid development of the cell and gene therapy industry [10]. Group 2: Elderly Care Services - Lishan Health emphasizes the importance of public welfare, developing high-quality elderly care projects like the Lishan International Jinchen Nursing Center and Lishan International Jinchen Luoyuan, addressing the growing health and elderly care needs [11][13]. - The Jinchen Nursing Center features a park-like environment and a comprehensive medical care system, with an investment of approximately 2.3 billion yuan, providing over 1,300 beds [11][12]. - The Jinchen Luoyuan project incorporates a personalized care system and collaborates with top hospitals to ensure efficient medical services for the elderly [13]. Group 3: Corporate Social Responsibility - As a state-owned enterprise, Lishan Health actively engages in social responsibility, contributing to industrial development and public welfare initiatives [14][18]. - The company aims to build a biopharmaceutical industry cluster in Jinan, enhancing the local industry chain and providing comprehensive support for enterprises [17]. - Lishan Health's volunteer service team organizes health consultations and free clinics, promoting health awareness among the elderly in the community [17].

司 章程 和元生物技术（上海）股份有限公司 章程 -3- 第一章 总 则 第一条 为了维护和元生物技术（上海）股份有限公司（以下简称"公司"或 "本公司"）、股东、职工和债权人的合法权益，规范公司的组织和行为，根据 《中华人民共和国公司法》（以下简称"《公司法》"）和其他相关法律、行政 法规和规范性文件有关规定，制订本章程。 和元生物技术（上海）股份有限公司 章 程 二〇二五年六月 和元生物技术（上海）股份有限公 司 章程 目 录 -2- 和元生物技术（上海）股份有限公 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司，采取发 起设立方式，由和元生物技术（上海）有限公司按原账面净资产值折股整体变更 设立的股份有限公司，在上海市市场监督管理局注册登记，取得营业执照。统一 社会信用代码为 913100000625940784。 第三条 公司于 2021 年 11 月 4 日经上海证券交易所（以下简称"交易所"） 核准并于 2022 年 1 月 11 日经中国证券监督管理委员会（以下简称"中国证监会"） 注册，首次向社会公众发行人民币普通股 10,000 万股，并于 2022 年 3 月 22 日在 上 ...

Group 1 - The core viewpoint of the articles highlights Sunlight Nuohe's innovative capabilities and growth potential in the pharmaceutical research and development sector, showcasing its integrated business ecosystem of "R&D services + pipeline cultivation + new quality industrial chain" [1] - The company has several innovative products in the R&D phase, covering various therapeutic areas such as autoimmune diseases, pain management, cardiology, central nervous system, oncology, metabolism, and respiratory diseases [1] - Sunlight Nuohe is committed to a dual-driven strategy of "independent innovation + technology transfer," establishing an international standard R&D platform and enhancing its industrial collaboration network to help domestic pharmaceutical companies overcome technical barriers and accelerate import substitution [1] Group 2 - The company is aligning with the trends in biomedicine, leveraging technological breakthroughs, policy support, and market demand, and has established a self-owned peptide innovation drug library screening system [2] - Currently, three innovative drugs have entered clinical stages, including STC007 for postoperative pain, which is in Phase II and soon to enter Phase III, and STC008 targeting cancer cachexia, which has completed Phase IA and is about to start Phase IB [2] - In the field of modified new drug development, the company focuses on sustained-release formulations and high-end formulations, with multiple technology platforms working together to design personalized sustained-release technologies [2] Group 3 - The company has made significant progress in its transdermal delivery research platform, with experience in gel patches and hot melt adhesives, and has partnered with Japan's KANEKA to introduce advanced transdermal patch technology [3] - Sunlight Nuohe is actively exploring the small nucleic acid drug field, which has substantial development potential, and is conducting in-depth research on chemical modifications and delivery systems for small nucleic acid drugs [3] - The company aims to enhance its R&D capabilities by absorbing global cutting-edge technologies and strives to secure a position in the global pharmaceutical market while contributing to the competitiveness of China's pharmaceutical industry [3]

医药生物/医疗服务 药石科技（300725.SZ） 2025Q1 营收增速稳健，海外市场贡献业绩核心弹性 2025 年 04 月 29 日 投资评级：买入（维持） | 日期 | 2025/4/28 | | --- | --- | | 当前股价(元) | 31.78 | | 一年最高最低(元) | 45.80/24.38 | | 总市值(亿元) | 63.47 | | 流通市值(亿元) | 53.52 | | 总股本(亿股) | 2.00 | | 流通股本(亿股) | 1.68 | | 近 3 个月换手率(%) | 302.2 | 司 信 息 更 新 报 告 股价走势图 -32% -16% 0% 16% 32% 48% 2024-04 2024-08 2024-12 药石科技 沪深300 数据来源：聚源 相关研究报告 《公司在手订单增速稳健，营收环比 恢 复 增 长 — 公 司 信 息 更 新 报 告 》 -2024.10.31 《在手订单增速稳健，CDMO 业务持 续赋能全球客户—公司信息更新报 告》-2024.8.19 余汝意（分析师） 聂媛媛（联系人） yuruyi@kysec.cn 证书编号：S0790 ...

2025 年 04 月 29 日 药石科技(300725.SZ) 订单逐步改善，期待公司经营边际优化 事件： 公司发布了 2024 年年度报告和 2025 年第一季度报告，2024 年公司 分别实现营收和归母净利润 16.89 亿元和 2.20 亿元，分别同比下降 2.12%和同比增长 11.24%；2025Q1 公司分别实现营收和归母净利润 4.55 亿元和 0.36 亿元，分别同比增长 20.55%和同比下降 27.67%。 受产品价格竞争和短期盈利能力承压等影响，2025Q1 业绩暂时 性下滑： 2024 年公司分别实现营收和归母净利润 16.89 亿元和 2.20 亿元，分 别同比下降 2.12%和同比增长 11.24%。其中，2024 年药物研究阶段 的产品和服务、药物开发及商业化阶段的产品和服务分别贡献营收 3.31 亿元（-4.06%）、13.54 亿元（-1.83%）。 2025Q1 公司分别实现营收和归母净利润 4.55 亿元和 0.36 亿元，分 别同比增长 20.55%和同比下降 27.67%。其中，2025Q1 药物研究阶段 的产品和服务、药物开发及商业化阶段的产品和服务分别贡献营收 ...